Stac, If Direct's Ph1 results to-date are WOW and truly indicate an ability for NWBO DC's to overcome local and systemic immune suppression by the tumor, then I've got to believe there will not only be a company PR Tue or Wed well in advance of the SITC Poster Exhibit on Friday, Nov 7th but also some sort of investor conference call the following week to explain what this means for the company.
That would be in addition to (or because):
- publishing the scientific abstract on SITC's Journal for ImmunoTherapy of Cancer which lay people might not understand and most do not read
- MD Anderson doctors at the booth communicating with visitors on a one-on-one basis which nobody can listen in on.
Market Data 
Markets 
AI
